Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2000-12-04
2008-05-06
Wehbe′, Anne Marie (Department: 1632)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S402000
Reexamination Certificate
active
07368532
ABSTRACT:
A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a HNdomain of a clostridial toxin and is not a fragment or derivative of a HNdomain of a clostridial toxin.
REFERENCES:
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5668255 (1997-09-01), Murphy
patent: 5989545 (1999-11-01), Foster et al.
patent: 6395513 (2002-05-01), Foster et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: 2002/0044950 (2002-04-01), Shone et al.
patent: 2003/0049264 (2003-03-01), Foster et al.
patent: 2003/0166238 (2003-09-01), Shone et al.
patent: 2004/0071736 (2004-04-01), Quinn et al.
patent: 0 439 954 (1991-08-01), None
patent: WO 99/09057 (1999-02-01), None
patent: WO 99/17806 (1999-04-01), None
patent: WO 00/28041 (2000-05-01), None
patent: WO 01/19863 (2001-03-01), None
patent: WO 01/36588 (2001-05-01), None
Francis, et al. (2004, Brain Research, 995:84-96).
Halpern and Loftus (1993, JBC, 268:11188-11192).
Kim et al., 2002, Stroke, 33: 809-815.
Martin et al., 1998, Brain Research Bulletin, 46: 281-309.
Humeau et al. 2000, Biocheimie, 82: 427-446.
Mitsuya et al., 1985, PNAS, USA, 82: 7096-7100.
Agrawal and Kanimalla 2000, Molecular Medicine Today, 61: 72-81.
Figueiredo et al. 1997, Experimental Neurology, 145: 546-554.
Lacy. et al., 1998, Nature Structural Biology, 5: 898-902.
Application and Prosecution History for “Recombinant Toxin Fragments,” Shone et al., U.S. Appl. No. 09/255,829, filed Feb. 23, 1999.
Application and Prosecution History for “Conjugates of Galatose-Binding Lectins and Clostridial Neurotoxins as Analgesics,” Duggan et al., U.S. Appl. No. 09/529,130, with a §371 date Jun. 22, 2000.
Application and Prosecution History for “Methods and Compounds for the Treatment of Mucus Hypersecretion,” Quinn et al., U.S. Appl. No. 09/763,669, with a §371 date May 29, 2001.
Application and Prosecution History for “Delivery of Superoxide Dismutase to Neuronal Cells,” Shone et al., U.S. Appl. No. 09/831,050, with a §371 date of Aug. 20, 2001.
Application and Prosecution History for “Recombinant Toxin Fragments,” Shone et al., U.S. Appl. No. 10/241,596, filed Sep. 12, 2002.
Application and Prosecution History for “Methods and Compounds for the Treatment of Mucus Hypersecretion,” Quinn et al., U.S. Appl. No. 10/633,698, filed Aug. 5, 2003.
Shone et al., “Delivery of Superoxide Dismutase to Neuronal Cells,” U.S. Appl. No. 11/062,471, filed Feb. 22, 2005.
Shone et al., “Recombinant Toxin Fragments,” U.S. Appl. No. 11/077,550, filed Mar. 11, 2005.
Shone et al., “Recombinant Toxin Fragments,” U.S. Appl. No. 10/527,411, filed Mar. 11, 2005.
International Search Report mailed Nov. 26, 2001 for International Application No. PCT/GB00/04644.
Helenius, A., et al., “Viruses as Tools in Drug Delivery,”Annels of the New York Academy of Sciences, 507:1-6, New York Academy of Sciences (1987).
NLM Gateway abstract for Decout, A., et al., “Enhanced efficiency of a targeted fusogenic peptide,”Biochim. Biophys. Acta. 1372:102-116, Elsevier Science B.V. (1998), accessed online Nov. 19, 2002 at <URL: http://gateway.nlm.nih.gov/gw/Cmd?GMResults>.
NLM Gateway abstract for Efremov, R.G., et al., “Factors important for fusogenic activity of peptides: molecular modeling study of analogs of fusion peptide of influenza virus hemagglutinin,”FEBS Lett. 462: 205-210, Elsevier Science B.V. (1999), accessed online Nov. 19, 2002 at <URL: http://gateway.nlm.nih.gov/gw/Cmd?GMResults>.
NLM Gateway abstract for Kichler, A., et al., “Glycofection in the presence of anionic fusogenic peptides: a study of the parameters affecting the peptide-mediated enhancement of the transfection efficiency,”J. Gene Med. 1: 134-143, John Wiley and Sons, Ltd. (1999), accessed online Nov. 19, 2002 at <URL: http://gateway.nlm.nih.gov/gw/Cmd?GMResults>.
NLM Gateway abstract for Martin, I., et al., “Membrane fusion induced by a short fusogenic peptide is assessed by its insertion and orientation into target bilayers,”Biochemistry, 38: 9337-9347, American Chemical Society (1999), accessed online Nov. 19, 2002 at <URL: http://gateway.nlm.nih.gov/gw/Cmd?GMResults>.
NLM Gateway abstract for Tolstikov, V.V., et al., “Influence of endosome-destabilizing peptides on efficacy of anti-HIV immunotoxins,”Bioconjug. Chem., 8: 38-43, American Chemical Society (1997), accessed online Nov. 19, 2002 at <URL: http://gateway.nlm.nih.gov/gw/Cmd?GMResults>.
NLM Gateway abstract for Wagner, E., et al., “Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by tranferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle,”Proc. Natl. Acad. Sci. U.S.A., 89: 7934-7938, National Academy of Sciences (1992), accessed online Nov. 19, 2002 at <URL: http://gateway.nlm.nih.gov/gw/Cmd? GMResults>.
Shone Clifford Charles
Silman Nigel
Sutton John Mark
Hama Joanne
Sterne, Kessler, Goldstein & Fox P.L.L.C
Syntaxin Limited
Wehbe′ Anne Marie
LandOfFree
Constructs for delivery of therapeutic agents to neuronal cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Constructs for delivery of therapeutic agents to neuronal cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Constructs for delivery of therapeutic agents to neuronal cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3984222